KeyBank National Association
CRNX icon

KeyBank National Association’s Crinetics Pharmaceuticals CRNX Stock Holding History

KeyBank National Association’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,357
Closed -$249K – 1252
2025
Q4 		$249K Sell
5,357
-2,778
-34% -$124K ﹤0.01% 1083
2025
Q3 		$339K Hold
8,135
– – ﹤0.01% 955
2025
Q2 		$234K Hold
8,135
– – ﹤0.01% 1075
2025
Q1 		$273K Sell
8,135
-1,217
-13% -$45.5K ﹤0.01% 1004
2024
Q4 		$478K Buy
9,352
+1,176
+14% +$65.8K ﹤0.01% 805
2024
Q3 		$418K Buy
8,176
+6
+0.1% +$309 ﹤0.01% 856
2024
Q2 		$366K Buy
8,170
+489
+6% +$22.6K ﹤0.01% 861
2024
Q1 		$360K Buy
7,681
+235
+3% +$9.2K ﹤0.01% 881
2023
Q4 		$265K Buy
+7,446
New +$228K ﹤0.01% 960

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

KeyBank National Association's CRNX Position: Q1 2026 in Review

KeyBank National Association sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 5,357 shares — an estimated $249K sold.

KeyBank National Association first reported a position in CRNX in Q4 2023 and held it in 9 quarters. The position peaked at $478K in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • KeyBank National Association reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • KeyBank National Association sold 5,357 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $249K.
  • KeyBank National Association first reported a position in Crinetics Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • KeyBank National Association's Crinetics Pharmaceuticals position peaked at $478K in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on KeyBank National Association's 13F filing for Q1 2026, filed 24 Apr 2026.